May 15 – 20, 2022
Casino Conference Centre
Europe/Prague timezone

Development of 211At-Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated Cancer

May 17, 2022, 4:35 PM
Red Hall

Red Hall


Chiara Timperanza (University of Gothenburg)


To enhance the therapeutic efficacy of radioimmunotherapy of cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumour is pretargeted with a modified monoclonal antibody that has affinity for both, tumour antigen and radiolabeled carrier. A big challenge in cancer treatment is the elimination of occult disseminated tumour cells, in this context the alpha emitter 211At has drawn attention due to its physicochemical characteristics. This project aims to design new molecules for pretargeting applications based on the Diels Alder click chemistry system (Tetrazine (Tz)/Trans-cyclooctene (Tco)) using 211At as radionuclide, and to evaluate these substances to optimize the pharmacokinetics.

Presentation materials

There are no materials yet.